drugset / Trial / NCT06889376

Use of Intranasal Midazolam to Reduce Stress and Procedural Pain in Premature Infants During Routine ROP Examination.

NCT06889376 ↗

Phase 1 Not yet recruiting 40 enrolled Polish Mother Memorial Hospital Research Institute
RandomizedParallel-groupOpen-labelOther

Summary

The goal of this study is to learn about the safety and effectiveness of intranasal midazolam in newborns and infants born prematurely, undergoing Retinopathy of Prematurity (ROP) screening. The main question it aims to answer is: • Does use of intranasal midazolam is a safe, quick, non-invasive medication, that reduces the pain, stress, discomfort, and other complications in patients undergoing ROP screening? Researchers will compare the intervention group with a comparison group of the patients who will receive routine comfort care.

Timeline

Start
2025-03-24
Primary completion
2025-06-01
Completion
2025-07-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 0.2 mg/kg Intranasal

Indications

No indication recorded.